AU2016307889A1 - Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors - Google Patents
Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors Download PDFInfo
- Publication number
- AU2016307889A1 AU2016307889A1 AU2016307889A AU2016307889A AU2016307889A1 AU 2016307889 A1 AU2016307889 A1 AU 2016307889A1 AU 2016307889 A AU2016307889 A AU 2016307889A AU 2016307889 A AU2016307889 A AU 2016307889A AU 2016307889 A1 AU2016307889 A1 AU 2016307889A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- compound according
- mmol
- fluoro
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- DZRIXLUFXJVNSI-UHFFFAOYSA-N O=Cc(cn1)cc2c1[o]c1c2nc(-c2cccc3c2cc[nH]3)nc1N1CCOCC1 Chemical compound O=Cc(cn1)cc2c1[o]c1c2nc(-c2cccc3c2cc[nH]3)nc1N1CCOCC1 DZRIXLUFXJVNSI-UHFFFAOYSA-N 0.000 description 5
- 0 CN(*)Cc(cn1)cc2c1[o]c1c2nc(-c2c(cc[n]3)c3ccc2)nc1N1CCOCC1 Chemical compound CN(*)Cc(cn1)cc2c1[o]c1c2nc(-c2c(cc[n]3)c3ccc2)nc1N1CCOCC1 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C Chemical compound CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- NDOVLWQBFFJETK-UHFFFAOYSA-N O=S1(CCNCC1)=O Chemical compound O=S1(CCNCC1)=O NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 2
- RKIRNQUUFNADPX-UHFFFAOYSA-N O=S1CCN(Cc(cc2c3n4)cnc2[o]c3c(N2CCOCC2)nc4Cl)CC1 Chemical compound O=S1CCN(Cc(cc2c3n4)cnc2[o]c3c(N2CCOCC2)nc4Cl)CC1 RKIRNQUUFNADPX-UHFFFAOYSA-N 0.000 description 2
- CAWRLEYAOIYGPN-ROUUACIJSA-N C(c(cc12)cnc1[o]c1c2nc(-c2c(cc[nH]3)c3ccc2)nc1N1CCOCC1)N1[C@@H](C2)CS[C@@H]2C1 Chemical compound C(c(cc12)cnc1[o]c1c2nc(-c2c(cc[nH]3)c3ccc2)nc1N1CCOCC1)N1[C@@H](C2)CS[C@@H]2C1 CAWRLEYAOIYGPN-ROUUACIJSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N C1NCCSC1 Chemical compound C1NCCSC1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- LTQBUWVDIKUNHJ-WHFBIAKZSA-N C1[C@@H]2SC[C@H]1NC2 Chemical compound C1[C@@H]2SC[C@H]1NC2 LTQBUWVDIKUNHJ-WHFBIAKZSA-N 0.000 description 1
- STRAMSCPUJKXDU-UHFFFAOYSA-N CC(NC1N2CCOCC2)=Nc2c1[o]c1ncc(C=O)cc21 Chemical compound CC(NC1N2CCOCC2)=Nc2c1[o]c1ncc(C=O)cc21 STRAMSCPUJKXDU-UHFFFAOYSA-N 0.000 description 1
- TYSSDDNGMHOPRP-UHFFFAOYSA-N CC(c(cc12)cnc1[o]c(c(N1CCOCC1)n1)c2nc1Cl)N(CC1)CCS1(=O)=O Chemical compound CC(c(cc12)cnc1[o]c(c(N1CCOCC1)n1)c2nc1Cl)N(CC1)CCS1(=O)=O TYSSDDNGMHOPRP-UHFFFAOYSA-N 0.000 description 1
- JUAGBRCZHMHUFN-UHFFFAOYSA-N CC1(C)OB(c2c(cc[nH]3)c3cc(Cl)c2)OC1(C)C Chemical compound CC1(C)OB(c2c(cc[nH]3)c3cc(Cl)c2)OC1(C)C JUAGBRCZHMHUFN-UHFFFAOYSA-N 0.000 description 1
- QDCIXBBEUHMLDN-UHFFFAOYSA-N CC1(C)OB(c2c(cc[nH]3)c3ccc2)OC1(C)C Chemical compound CC1(C)OB(c2c(cc[nH]3)c3ccc2)OC1(C)C QDCIXBBEUHMLDN-UHFFFAOYSA-N 0.000 description 1
- DOARAXALTUDURU-UHFFFAOYSA-N CNCc(cn1)cc2c1[o]c1c2nc(-c2c(cc[nH]3)c3ccc2)nc1N1CCOCC1 Chemical compound CNCc(cn1)cc2c1[o]c1c2nc(-c2c(cc[nH]3)c3ccc2)nc1N1CCOCC1 DOARAXALTUDURU-UHFFFAOYSA-N 0.000 description 1
- IVLSLXMGGISLJT-MRVPVSSYSA-N C[C@H](c(cc12)cnc1[o]c(c(N1CCOCC1)n1)c2nc1Cl)N Chemical compound C[C@H](c(cc12)cnc1[o]c(c(N1CCOCC1)n1)c2nc1Cl)N IVLSLXMGGISLJT-MRVPVSSYSA-N 0.000 description 1
- ASAAICTVGLYLRH-UHFFFAOYSA-N Cc(nc1N2CCOCC2)nc2c1[o]c1ncc(C=O)cc21 Chemical compound Cc(nc1N2CCOCC2)nc2c1[o]c1ncc(C=O)cc21 ASAAICTVGLYLRH-UHFFFAOYSA-N 0.000 description 1
- AYQRUVBPLGICNU-UHFFFAOYSA-N Cc1nc(N2CCOCC2)c2[o]c3ncc(CN(CC4)CCS4=O)cc3c2n1 Chemical compound Cc1nc(N2CCOCC2)c2[o]c3ncc(CN(CC4)CCS4=O)cc3c2n1 AYQRUVBPLGICNU-UHFFFAOYSA-N 0.000 description 1
- JSHJFDUDNNDHOX-STQMWFEESA-N Clc(nc1N2CCOCC2)nc2c1[o]c1ncc(CN3[C@@H](C4)CS[C@@H]4C3)cc21 Chemical compound Clc(nc1N2CCOCC2)nc2c1[o]c1ncc(CN3[C@@H](C4)CS[C@@H]4C3)cc21 JSHJFDUDNNDHOX-STQMWFEESA-N 0.000 description 1
- PMIGAISGWPTELT-UHFFFAOYSA-N N#Cc1c[nH]c2cccc(Br)c12 Chemical compound N#Cc1c[nH]c2cccc(Br)c12 PMIGAISGWPTELT-UHFFFAOYSA-N 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N O=S1CCNCC1 Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- USJUQEVUEBCLLR-UHFFFAOYSA-N OB(c1cccc2c1cc[nH]2)O Chemical compound OB(c1cccc2c1cc[nH]2)O USJUQEVUEBCLLR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1514754.9A GB201514754D0 (en) | 2015-08-19 | 2015-08-19 | Compounds |
| GB1514754.9 | 2015-08-19 | ||
| PCT/GB2016/052581 WO2017029521A1 (en) | 2015-08-19 | 2016-08-19 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016307889A1 true AU2016307889A1 (en) | 2018-03-08 |
Family
ID=54258853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016307889A Abandoned AU2016307889A1 (en) | 2015-08-19 | 2016-08-19 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10442815B2 (enExample) |
| EP (1) | EP3337807A1 (enExample) |
| JP (1) | JP2018528942A (enExample) |
| CN (1) | CN108349988B (enExample) |
| AU (1) | AU2016307889A1 (enExample) |
| CA (1) | CA2995909A1 (enExample) |
| GB (1) | GB201514754D0 (enExample) |
| MX (1) | MX2018001992A (enExample) |
| WO (1) | WO2017029521A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597983A (en) | 2009-08-20 | 2014-05-30 | Karus Therapeutics Ltd | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| JP7290627B2 (ja) | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| GB201909468D0 (en) | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
| WO2021113633A1 (en) | 2019-12-05 | 2021-06-10 | Verge Analytics, Inc. | Fused tricyclic heterocyclic compounds as inhibitors of pikfyve kinase useful for the treatment of neurological diseases |
| US12486274B2 (en) | 2020-01-13 | 2025-12-02 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
| WO2022169882A1 (en) | 2021-02-03 | 2022-08-11 | Verge Analytics, Inc. | Methods and treatment of viral infection caused by sars-cov-2 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445742A1 (de) | 1963-11-06 | 1968-12-19 | Bayer Ag | Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen |
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| AU5261001A (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| WO2002002551A1 (en) | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| EP1521747B1 (en) | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2557541C (en) | 2004-02-26 | 2014-12-16 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivatives |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| JP2008545660A (ja) | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| KR20090021155A (ko) | 2006-04-26 | 2009-02-27 | 에프. 호프만-라 로슈 아게 | Ｐｉ3ｋ 억제제로서의 피리미딘 유도체 |
| AU2007243466B2 (en) | 2006-04-26 | 2012-01-19 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| WO2008001076A1 (en) * | 2006-06-26 | 2008-01-03 | Ucb Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
| EP2441768A1 (en) | 2006-11-13 | 2012-04-18 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
| EP2121613A2 (en) | 2007-01-31 | 2009-11-25 | Vertex Pharmaceuticals, Inc. | 2-aminopyridine derivatives useful as kinase inhibitors |
| EP2139332A4 (en) | 2007-03-28 | 2010-04-21 | Merck Sharp & Dohme | SUBSTITUTED PYRIDO [2,3-D] PYRIMIDIN DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS |
| EP2154965A4 (en) | 2007-05-29 | 2011-08-17 | Glaxosmithkline Llc | NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| JP2011529932A (ja) | 2008-08-05 | 2011-12-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ナフチリジン及び医薬としてのその使用 |
| WO2010037765A2 (en) | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| US8981087B2 (en) | 2009-07-29 | 2015-03-17 | Karus Therapeutics Limited | Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
| NZ597983A (en) * | 2009-08-20 | 2014-05-30 | Karus Therapeutics Ltd | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| DK3686193T3 (da) | 2011-07-27 | 2022-05-30 | Astrazeneca Ab | 2-(2,4,5-substitueret anilino)pyrimidinforbindelser |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| EP3181564B1 (en) | 2012-11-20 | 2019-09-18 | H. Hoffnabb-La Roche Ag | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| SI2994465T1 (sl) | 2013-05-10 | 2018-10-30 | Karus Therapeutics Limited | Novi inhibitorji histon deacetilaze |
| KR20160013204A (ko) | 2013-05-30 | 2016-02-03 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료 |
| WO2014210354A1 (en) * | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| ES2818933T3 (es) | 2013-10-10 | 2021-04-14 | Acetylon Pharmaceuticals Inc | Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin |
| GB201321730D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321729D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201402431D0 (en) * | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201514751D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514756D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
-
2015
- 2015-08-19 GB GBGB1514754.9A patent/GB201514754D0/en not_active Ceased
-
2016
- 2016-08-19 US US15/753,358 patent/US10442815B2/en active Active
- 2016-08-19 EP EP16756767.6A patent/EP3337807A1/en not_active Withdrawn
- 2016-08-19 AU AU2016307889A patent/AU2016307889A1/en not_active Abandoned
- 2016-08-19 WO PCT/GB2016/052581 patent/WO2017029521A1/en not_active Ceased
- 2016-08-19 MX MX2018001992A patent/MX2018001992A/es unknown
- 2016-08-19 CN CN201680058333.7A patent/CN108349988B/zh active Active
- 2016-08-19 CA CA2995909A patent/CA2995909A1/en not_active Abandoned
- 2016-08-19 JP JP2018508666A patent/JP2018528942A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018001992A (es) | 2018-06-19 |
| CN108349988A (zh) | 2018-07-31 |
| CN108349988B (zh) | 2021-10-01 |
| WO2017029521A1 (en) | 2017-02-23 |
| EP3337807A1 (en) | 2018-06-27 |
| US20180244685A1 (en) | 2018-08-30 |
| CA2995909A1 (en) | 2017-02-23 |
| JP2018528942A (ja) | 2018-10-04 |
| GB201514754D0 (en) | 2015-09-30 |
| US10442815B2 (en) | 2019-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10442815B2 (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| US11708378B2 (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| KR20250113487A (ko) | 화합물 | |
| EP2822943B1 (en) | Phosphoinositide 3-kinase inhibitors | |
| US10377764B2 (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| KR20180063895A (ko) | 단백질 키나제 억제제로서의 벤조락탐 화합물 | |
| WO2021092336A1 (en) | Heterocyclic rip1 inhibitory compounds | |
| CN108348505A (zh) | 包含磷酸肌醇3-激酶抑制剂和第二抗增殖剂的组合物 | |
| BR112021006905A2 (pt) | composto, sal e solvato do mesmo e agente agonístico de sting, composição farmacêutica que compreende o dito composto e uso do mesmo para suprimir a progressão de, suprimir a recorrência de e/ou tratar câncer ou doença infecciosa | |
| RU2797295C1 (ru) | Изоиндолиноновые ингибиторы взаимодействия mdm2-p53, обладающие противораковой активностью | |
| HK1227870A1 (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| HK1227870B (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |